Authors: Tomohiko Kamimura Toshihiro Miyamoto Shuichiro Takashima Noriko Yokota Yong Chong Yoshikiyo Ito Koichi Akashi
Publish Date: 2012/09/08
Volume: 96, Issue: 4, Pages: 525-527
Abstract
The proteasome inhibitor bortezomib Bor is important in the management of multiple myeloma MM However when administered intravenously its efficacy can be limited by significant exacerbation of peripheral neuropathy PN 1 Recently Moreau reported that the response rate in patients treated with subcutaneous Bor sBor was nearly equal to that in patients treated with intravenous Bor ivBor although the incidence and severity of PN in patients treated with sBor was lower than those in patients treated with ivBor 2 3 4 The most common injection site reaction was erythema however only four patients 3 developed an injection site reaction of grade 3 or more necessitating a reduction in Bor dose in two 1 patients 3 The injection site reactions in the other two patients treated with sBor were severe although detailed information regarding the clinical courses following these reactions was not provided 3 According to a classification of skin symptoms Bor is
Keywords: